Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Trauma
Conditions
Trauma, Pain
Trial Timeline
Oct 1, 2015 → Dec 1, 2016
NCT ID
NCT02616068About Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch)
Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch) is a phase 3 stage product being developed by Daiichi Sankyo for Trauma. The current trial status is completed. This product is registered under clinical trial identifier NCT02616068. Target conditions include Trauma, Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02616068 | Phase 3 | Completed |
Competing Products
20 competing products in Trauma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product | Sun Pharmaceutical | Phase 1 | 33 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| SYN117 (nepicastat) + Placebo comparator | Johnson & Johnson | Phase 2 | 52 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 77 |
| Adjunctive asenapine | Merck | Approved | 85 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| Alendronate | Merck | Approved | 85 |
| Iloperidone + Placebo | Novartis | Phase 2 | 52 |
| AMG 334 | Novartis | Phase 2 | 52 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |